Mabylon Study Links IgG4 Antibodies to Allergy Tolerance
Researchers report allergen-specific IgG4 antibodies redirect allergens toward immune cells that promote tolerance-associated responses.
Updated on Nov. 5, 2026 in Allergies
Mabylon AG announced publication of a study in Clinical & Experimental Allergy showing that allergen-specific IgG4 antibodies redirect allergens away from B cells and toward myeloid antigen-presenting cells. The findings were drawn from experiments using cells from peanut-allergic patients and a mouse model of peanut allergy.
Why it matters
The results suggest a mechanism by which antibody-based approaches could shift the immune response in allergic disease toward tolerance rather than sensitization. Mabylon plans to monitor markers of disease modification in its MY006 and MY010 programs.
The findings come from ex vivo experiments on cells from peanut-allergic patients and a mouse model of peanut allergy, with the mouse data showing that IgG4 prevented the rise in allergen-specific IgE during oral immunotherapy. Whether these results hold in human patients over time remains untested.
The players
Mabylon AG
A Swiss biotechnology company developing antibody-based therapies for allergic diseases, including the MY006 and MY010 programs.
Clinical & Experimental Allergy
The official journal of the British Society for Allergy & Clinical Immunology, which published the study.
The details
Allergen-specific IgG4 antibodies were shown to neutralize allergens and steer them toward antigen-presenting immune cells, reducing type 2 inflammatory cytokines and increasing IL-10 and regulatory T-cell responses. In a mouse model, combining these antibodies with controlled allergen exposure reduced mast-cell activation. The same redirection was observed with birch-specific IgG4 and the birch pollen allergen Bet v 1.
Timeline
November 5, 2026: Mabylon announced publication of the study.
2027: Clinical trials of MY010 are expected to start.
Big Picture
The study builds on oral allergen immunotherapy for peanut allergy, which in mouse experiments was accompanied by a rise in allergen-specific IgE that IgG4 antibodies prevented. It positions antibody-based redirection of allergens as a possible complement to established desensitization approaches.
For people with peanut or tree-pollen allergies, this research points toward future treatments that could reduce allergic reactions rather than only manage them. No new treatment is available yet, and the work remains at the laboratory and early clinical stage.
The takeaway
Allergen-specific antibodies may one day help the immune system learn tolerance instead of reacting, but patients should rely on established allergy care until clinical results are available.
What happens next
Clinical trials of MY010 are expected to begin in 2027, and clinical studies will determine whether the tolerance-associated effects seen in the lab translate into durable disease modification in patients.
Further reading
For more on the conditions behind this research, see our Allergies coverage.
Source note: This article includes information reported by Pharmabiz.
